Recherche
Résultats 1-10 de 38
-
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059
BLOOD, 05-2017, 129 (20), 2808-2810Article dans une revue scientifique -
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Journal of clinical oncology, 2017, 35, 2473Article dans une revue scientifique -
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Journal of clinical oncology, 2017, 35, 552Article dans une revue scientifique -
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
Human pathology, 2017, 64, 128-136Article dans une revue scientifique -
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
American journal of hematology, 2016, 91, 179-184Article dans une revue scientifique -
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Lancet (London, England), 2016, 387, 2402-2411Article dans une revue scientifique -
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
The Lancet. Oncology, 2015, 16, 704-715Article dans une revue scientifique -
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group
Haematologica, 2016, 101, 474-481Article dans une revue scientifique -
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
Leukemia, 2015, 29, 1578-1586Article dans une revue scientifique -
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Leukemia, 2018Article dans une revue scientifique